{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:58:33Z","timestamp":1787320713669,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015400","name":"Fonds Erasme","doi-asserted-by":"publisher","award":["Fonds Erasme"],"award-info":[{"award-number":["Fonds Erasme"]}],"id":[{"id":"10.13039\/100015400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02271-4","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:59:03Z","timestamp":1787317143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intra-patient comparison of tracer uptake and biodistribution of [68Ga]Ga-FAPI-46 and [18F]AlF-FAPI-74"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-9208","authenticated-orcid":false,"given":"Anne-Leen","family":"Deleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bondue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u00e7a Ar\u00e7ay","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Vercauteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vanderlinden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Taraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philom\u00e8ne","family":"Lavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"De Bontridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00e9na","family":"Wimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"3","key":"2271_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"key":"2271_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060716","author":"D Albano","year":"2024","unstructured":"Albano D, Rizzo A, Slart R, Hess S, Noriega-Alvarez E, Wakfie-Corieh CG, et al. The role of fibroblast activation protein inhibitor positron emission tomography in inflammatory and infectious diseases: an updated systematic review. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17060716.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"2271_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2967\/jnumed.123.265471","volume":"64","author":"G Wass","year":"2023","unstructured":"Wass G, Clifford K, Subramaniam RM. Evaluation of the Diagnostic Accuracy of FAPI PET\/CT in Oncologic Studies: Systematic Review and Metaanalysis. J Nucl Med. 2023;64(8):1218\u201324.","journal-title":"J Nucl Med"},{"issue":"1","key":"2271_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori Y, Novruzov E, Schmitt D, Cardinale J, Watabe T, Choyke PL, et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). Npj Imaging. 2024;2(1):48.","journal-title":"Npj Imaging"},{"issue":"8","key":"2271_CR5","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","volume":"49","author":"M Li","year":"2022","unstructured":"Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49(8):2844\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2271_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"1","key":"2271_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","volume":"66","author":"TA Hope","year":"2025","unstructured":"Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025;66(1):26\u201333.","journal-title":"J Nucl Med"},{"issue":"6","key":"2271_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.121.262808","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D, et al. Pitfalls and common findings in (68)Ga-FAPI PET: a pictorial analysis. J Nucl Med. 2022;63(6):890\u20136.","journal-title":"J Nucl Med"},{"issue":"1142","key":"2271_CR9","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20220463","volume":"96","author":"M Hotta","year":"2023","unstructured":"Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, et al. Non-oncologic incidental uptake on FAPI PET\/CT imaging. Br J Radiol. 2023;96(1142):20220463.","journal-title":"Br J Radiol"},{"issue":"12","key":"2271_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2967\/jnumed.122.264069","volume":"63","author":"FM Glatting","year":"2022","unstructured":"Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, et al. Repetitive early (68)Ga-FAPI PET acquisition comparing (68)Ga-FAPI-02, (68)Ga-FAPI-46, and (68)Ga-FAPI-74: methodologic and diagnostic implications for malignant, inflammatory\/reactive, and degenerative lesions. J Nucl Med. 2022;63(12):1844\u201351.","journal-title":"J Nucl Med"},{"issue":"1","key":"2271_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-025-01356-x","volume":"16","author":"Y Hoda","year":"2025","unstructured":"Hoda Y, Shimizu K, Nishida H, Ikari Y, Akamatsu G, Matsumoto K, et al. Optimizing [(18)F]FAPI-74 PET\/CT imaging: insights from Early-phase tumor uptake and tissue contrast. EJNMMI Res. 2025;16(1):4.","journal-title":"EJNMMI Res"},{"issue":"8","key":"2271_CR12","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-021-05646-z","volume":"49","author":"K Hu","year":"2022","unstructured":"Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [(18)F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49(8):2833\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2271_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1053\/j.semnuclmed.2024.02.006","volume":"54","author":"T Higuchi","year":"2024","unstructured":"Higuchi T, Serfling SE, Leistner DM, Speer T, Werner RA. FAPI-PET in Cardiovascular Disease. Semin Nucl Med. 2024;54(5):747\u201352.","journal-title":"Semin Nucl Med"},{"issue":"5","key":"2271_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11307-024-01928-8","volume":"26","author":"L Wan","year":"2024","unstructured":"Wan L, Sun C, Liang J, Lin J, Chen Z. Volume-based quantitative measurement of [(18)F]AlF-NOTA-FAPI-04 PET\/CT uptake reflects the disease activity of IgG4-related disease. Mol Imaging Biol. 2024;26(5):753\u201360.","journal-title":"Mol Imaging Biol"},{"issue":"5","key":"2271_CR15","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1007\/s00259-025-07674-5","volume":"53","author":"KM Pabst","year":"2026","unstructured":"Pabst KM, Siegmund SC, Holzgreve A, Schmid HP, Bartel T, Herrmann K, et al. Potential value of [(68)Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis. Eur J Nucl Med Mol Imaging. 2026;53(5):3162\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2271_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11307-022-01759-5","volume":"25","author":"M Dabir","year":"2023","unstructured":"Dabir M, Novruzov E, Mattes-Gyorgy K, Beu M, Dendl K, Antke C, et al. Distinguishing benign and malignant findings on [(68) Ga]-FAPI PET\/CT based on quantitative SUV measurements. Mol Imaging Biol. 2023;25(2):324\u201333.","journal-title":"Mol Imaging Biol"},{"issue":"Suppl 1","key":"2271_CR17","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):S11\u201320.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2271_CR18","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02271-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:59:03Z","timestamp":1787317143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02271-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":18,"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02271-4","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors A.A.O., C.A., S.V., C.M., B.V., L.T., P.L., S.D.B., Z.W. and P.F. declare they have no financial interests. Author A.D. has received congress and travel support from Boehringer Ingelheim and Novartis. Author B.B. has received congress and travel support from Boehringer Ingelheim. Author S.L. is currently employed by Telix Pharmaceuticals. The research presented in this manuscript was conducted while S.L. was affiliated with the ULB (Universit\u00e9 Libre de Bruxelles). Telix had no role in the design, conduct, analysis, or interpretation of the study. The Department of Nuclear Medicine in the Jules Bordet Institute has received advisory fees related to FAPI from GE Healthcare. These payments were institutional and not related to the present study. None of the companies had any involvement in the design, conduct, analysis, interpretation or manuscript preparation of the present study.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of H\u00f4pital Erasme, Brussels (References: P2022\/587\/CCB B4062022000316).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}